Search

Your search keyword '"Villaescusa, Teresa"' showing total 20 results
Start Over Author "Villaescusa, Teresa"
20 results on '"Villaescusa, Teresa"'

1. Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers

Author

Rodríguez, Marta, Alonso-Alonso, Ruth, Tomás-Roca, Laura, Rodríguez-Pinilla, Socorro M., Manso-Alonso, Rebeca, Cereceda, Laura, Borregón, Jennifer, Villaescusa, Teresa, Córdoba, Raúl, Sánchez-Beato, Margarita, Fernández-Miranda, Ismael, Betancor, Isabel, Bárcena, Carmen, García, Juan F., Mollejo, Manuela, García-Cosio, Mónica, Martin-Acosta, Paloma, Climent, Fina, Caballero, Dolores, de la Fuente, Lorena, Mínguez, Pablo, Kessler, Linda, Scholz, Catherine, Gualberto, Antonio, Mondéjar, Rufino, and Piris, Miguel A.

Published
2021
Full Text
View/download PDF

2. ABCL-479 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients

Author

Alonso, David, primary, Navarro, Almudena, additional, Alejo, Elena, additional, García, María, additional, Queizan, José Antonio, additional, Cabero, Almudena, additional, Alonso, María Eugenia, additional, García-Bacelar, Ana, additional, Dávila, Julio, additional, Labrador, Jorge, additional, Fernández, Silvia, additional, Albarrán, Beatriz, additional, Aguilar, Carlos, additional, Pardal, Emilia, additional, de Cabo, Erick, additional, Peñarrubia, María Jesús, additional, Cidoncha, Borja, additional, Martínez, Gerardo, additional, Villaescusa, Teresa, additional, Navarro, José María, additional, Gómez, Sandra Patricia, additional, Puerta, Carlos, additional, García-Jaén, Pablo, additional, Zapata, Evelyn Gabriela, additional, Clavo, Diego, additional, Malaver, Rafael José, additional, Fuentes, Cristina Teresa, additional, Fernández, Adolfo, additional, Santos, Carmen, additional, Martín, Alejandro, additional, Alcoceba, Miguel, additional, and Gutiérrez, Carmen Norma, additional

Published
2023
Full Text
View/download PDF

3. POSTER: ABCL-479 17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients

Author

Alonso, David, primary, Navarro, Almudena, additional, Alejo, Elena, additional, García, María, additional, Queizan, José Antonio, additional, Cabero, Almudena, additional, Alonso, María Eugenia, additional, García-Bacelar, Ana, additional, Dávila, Julio, additional, Labrador, Jorge, additional, Fernández, Silvia, additional, Albarrán, Beatriz, additional, Aguilar, Carlos, additional, Pardal, Emilia, additional, de Cabo, Erick, additional, Peñarrubia, María Jesús, additional, Cidoncha, Borja, additional, Martínez, Gerardo, additional, Villaescusa, Teresa, additional, Navarro, José María, additional, Gómez, Sandra Patricia, additional, Puerta, Carlos, additional, García-Jaén, Pablo, additional, Zapata, Evelyn Gabriela, additional, Clavo, Diego, additional, Malaver, Rafael José, additional, Fuentes, Cristina Teresa, additional, Fernández, Adolfo, additional, Santos, Carmen, additional, Martín, Alejandro, additional, Alcoceba, Miguel, additional, and Gutiérrez, Carmen Norma, additional

Published
2023
Full Text
View/download PDF

4. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

Author

Puertas Martínez, Borja, González-Calle, Verónica, Sobejano-Fuertes, Eduardo, Escalante, Fernando, Queizán, José-Antonio, Bárez, Abelardo, Labrador, Jorge, Alonso-Alonso, José María, García de Coca, Alfonso, Cantalapiedra, Alberto, Villaescusa, Teresa, Aguilar, Carlos, Alejo, Elena, Rey-Bua, Beatriz, López-Corral, L., García-Sanz, Ramón, Puig, Noemi, Gutiérrez, Norma Carmen, Mateos, Maria Victoria, Puertas Martínez, Borja, González-Calle, Verónica, Sobejano-Fuertes, Eduardo, Escalante, Fernando, Queizán, José-Antonio, Bárez, Abelardo, Labrador, Jorge, Alonso-Alonso, José María, García de Coca, Alfonso, Cantalapiedra, Alberto, Villaescusa, Teresa, Aguilar, Carlos, Alejo, Elena, Rey-Bua, Beatriz, López-Corral, L., García-Sanz, Ramón, Puig, Noemi, Gutiérrez, Norma Carmen, and Mateos, Maria Victoria

Abstract

[Background]: New therapeutic strategies have improved the prognosis of multiple myeloma (MM), changing the accepted view of this disease from being incurable to treatable. [Methods]: We studied 1001 patients with MM between 1980 and 2020, grouping patients into ten-year periods by diagnosis 1980–1990, 1991–2000, 2001–2010 and 2011–2020. [Results]: After 65.1 months of follow-up, the median OS of the cohort was 60.3 months, and OS increased significantly over time: 22.4 months in 1980–1990, 37.4 months in 1991–2000, 61.8 months in 2001–2010 and 103.6 months in 2011–2020 (p < 0.001). Using novel agents in the front-line setting for myeloma patients yielded a significantly better OS than in those treated with conventional therapies, especially when combinations of at least two novel agents were used. The median OS of patients treated with the combination of at least two novel agents in induction was significantly prolonged compared to those treated with a single novel agent or conventional therapy in induction: 143.3 vs. 61.0 vs. 42.2 months (p < 0.001). The improvement was apparent in all patients regardless of age at diagnosis. In addition, 132 (13.2%) patients were long-term survivors (median OS ≥ 10 years). Some independent clinical predictors of long-term survival were identified: ECOG < 1, age at diagnosis ≤ 65 years, non-IgA subtype, ISS-1 and standard-risk cytogenetic. Achieving CR and undergoing ASCT were positively associated with >10 years of survival. [Conclusions]: The combination of novel agents appears to be the main factor for the improvement in survival in MM, which is becoming a chronic and even curable disease in a subtype of patients without high-risk features.

Published
2023

5. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

Author

Puertas, Borja, primary, González-Calle, Verónica, additional, Sobejano-Fuertes, Eduardo, additional, Escalante, Fernando, additional, Queizán, José A., additional, Bárez, Abelardo, additional, Labrador, Jorge, additional, Alonso-Alonso, José María, additional, García de Coca, Alfonso, additional, Cantalapiedra, Alberto, additional, Villaescusa, Teresa, additional, Aguilar-Franco, Carlos, additional, Alejo-Alonso, Elena, additional, Rey-Bua, Beatriz, additional, López-Corral, Lucía, additional, García-Sanz, Ramón, additional, Puig, Noemi, additional, Gutiérrez, Norma C., additional, and Mateos, María-Victoria, additional

Published
2023
Full Text
View/download PDF

6. Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction–Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial

Author

PCRAGA Study Group, the Spanish Stem Cell Transplantation Group, the Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases, and the Spanish Network for Research in Infectious Diseases, Aguado, José María, Vázquez, Lourdes, Fernández-Ruiz, Mario, Villaescusa, Teresa, Ruiz-Camps, Isabel, Barba, Pere, Silva, Jose T., Batlle, Montserrat, Solano, Carlos, Gallardo, David, Heras, Inmaculada, Polo, Marta, Varela, Rosario, Vallejo, Carlos, Olave, Teresa, López-Jiménez, Javier, Rovira, Montserrat, Parody, Rocío, and Cuenca-Estrella, Manuel

Published
2015

8. Mutational landscape of nodal peripheral T-cell lymphoma subtypes

Author

Tomas-Roca, Laura, primary, Rodriguez, Marta, additional, Alonso-Alonso, Ruth, additional, Cereceda, Laura, additional, Rodríguez-Pinilla, Socorro M, additional, Borregon, Jennifer, additional, Manso, Rebeca, additional, Villaescusa, Teresa, additional, Córdoba, Raúl, additional, Sánchez-Beato, Margarita, additional, Fernández-Miranda, Ismael, additional, Bárcena, Carmen, additional, García, Juan F, additional, Mollejo, Manuela, additional, García-Cosio, Mónica, additional, Martin-Acosta, Paloma, additional, Climent, Fina, additional, Caballero, Dolores, additional, and Piris, Miguel Angel, additional

Published
2021
Full Text
View/download PDF

9. Peripheral T-cell lymphoma: molecular profiling distinguishes subclasses, recognizes the tumor architecture and identifies prognostic markers

Author

Rodriguez-Moreno, Marta, primary, Tomás-Roca, Laura, additional, Alonso-Alonso, Ruth, additional, Manso-Alonso, Rebeca, additional, Cereceda, Laura, additional, Borregón, Jennifer, additional, Villaescusa, Teresa, additional, Córdoba, Raúl, additional, Sánchez-Beato, Margarita, additional, Fernández-Miranda, Ismael, additional, Betancor, Isabel, additional, Bárcena, Carmen, additional, García, Juan Fernando, additional, Mollejo, Manuela, additional, García-Cosio, Monica, additional, Martín-Acosta, Paloma, additional, Climent, Fina, additional, Caballero, Dolores, additional, Mondéjar, Rufino, additional, Kessler, Linda, additional, Scholz, Catherine, additional, Gualberto, Antonio, additional, Rodríguez-Pinilla, Socorro María, additional, and Piris, Miguel Ángel, additional

Published
2021
Full Text
View/download PDF

10. Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT

Author

Cabero Martínez, Almudena, Diaz Gonzalez, Luis Gonzaga, Montes, Carlos, Cortés-Rodríguez, María, Gutierrez, Norma C., Baile Gonzalez, Monica, García Bacelar, Ana, Lopez Parra, Miriam, Cañadas, Jose Cristobal, Villanueva, Juan Gabriel, Diaz Galvez, Francisco Javier, Peñarrubia-Ponce, María, Fernandez Ferrero, Silvia Maria, Queizan Hernandez, Jose Antonio, Cabezudo, Miguel, De Cabo López, Erik, Villaescusa, Teresa, Tamayo, Pilar, Garcia-Sanz, Ramon, and Martin García-Sancho, Alejandro

Published
2023
Full Text
View/download PDF

11. Bio-P-16 - Peripheral T-cell lymphoma: molecular profiling distinguishes subclasses, recognizes the tumor architecture and identifies prognostic markers

Author

Rodriguez-Moreno, Marta, Tomás-Roca, Laura, Alonso-Alonso, Ruth, Manso-Alonso, Rebeca, Cereceda, Laura, Borregón, Jennifer, Villaescusa, Teresa, Córdoba, Raúl, Sánchez-Beato, Margarita, Fernández-Miranda, Ismael, Betancor, Isabel, Bárcena, Carmen, García, Juan Fernando, Mollejo, Manuela, García-Cosio, Monica, Martín-Acosta, Paloma, Climent, Fina, Caballero, Dolores, Mondéjar, Rufino, Kessler, Linda, Scholz, Catherine, Gualberto, Antonio, Rodríguez-Pinilla, Socorro María, and Piris, Miguel Ángel

Published
2021
Full Text
View/download PDF

12. Bio-O2-08 - Mutational landscape of nodal peripheral T-cell lymphoma subtypes

Author

Tomas-Roca, Laura, Rodriguez, Marta, Alonso-Alonso, Ruth, Cereceda, Laura, Rodríguez-Pinilla, Socorro M, Borregon, Jennifer, Manso, Rebeca, Villaescusa, Teresa, Córdoba, Raúl, Sánchez-Beato, Margarita, Fernández-Miranda, Ismael, Bárcena, Carmen, García, Juan F, Mollejo, Manuela, García-Cosio, Mónica, Martin-Acosta, Paloma, Climent, Fina, Caballero, Dolores, and Piris, Miguel Angel

Published
2021
Full Text
View/download PDF

13. The Brief Gah Scale (Geriatric Assessment in Hematology) Correlates Well with a Comprehensive Geriatric Assessment in Patients with Hematologic Malignancies

Author

Cordoba, Raul, primary, Hormigo, Ana-Isabel, additional, Martinez-Peromingo, Javier, additional, Jarana, Maria, additional, Perez-Albacete, Marta, additional, Villaescusa, Teresa, additional, Askari, Elham, additional, Lopez Lorenzo, Jose Luiz, additional, Perez-Saenz, Maria Angeles, additional, Prieto, Elena, additional, and Llamas Sillero, Maria Pilar, additional

Published
2018
Full Text
View/download PDF

14. Uveitis and Myositis as Immune Complications in Chemorefractory NK/T-Cell Nasal-Type Lymphoma Successfully Treated with Allogeneic Stem-Cell Transplant

Author

Gómez-Crespo, Maria José, García-Raso, Aránzazu, López-Lorenzo, Jose Luis, Villaescusa, Teresa, Rodríguez-Pinilla, María, Fortes, José, Serrano, Cristina, Machan, Salma, Llamas, Pilar, and Córdoba, Raúl

Subjects
Article Subject
Abstract

NK/T-cell lymphomas are a group of clonal proliferations of NK- or, rarely, T-cell types and have peculiar clinicopathologic features. Most common site of involvement is the upper aerodigestive tract (nasal cavity, nasopharynx, paranasal sinuses, and palate). Association of autoimmune paraneoplastic disorders with NK/T-cell lymphomas is not well studied. Our patient was diagnosed with NK/T-cell lymphoma stage IV with skin involvement and treated frontline with CHOEP regimen. While he was under treatment, two immune complications presented: anterior uveitis of autoimmune origin refractory to steroids and myositis in lower limbs muscles. Autologous transplantation was rejected due to confirmed early relapse after first-line treatment, and the patient received second-line treatment according to the SMILE scheme, reaching complete response after four cycles. The patient underwent allogeneic transplantation and at the time of manuscript preparation is alive despite multiple complications. The disease should be suspected in patients with rhinitis or recurrent sinusitis, and early biopsy is recommended for all patients to avoid a delay in diagnosis. Our patient also presented symptoms of disease progression after first-line treatment, representing a paraneoplastic process, a very rare phenomenon in T-type lymphomas. This case is novel for the appearance of an inflammatory myositis, a histologically verified paraneoplastic phenomenon that responded to treatment for lymphoma.

Published
2016
Full Text
View/download PDF

15. Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.

Author

Villaescusa, Teresa, Vázquez, Lourdes, Bergua, Juan Miguel, García, Julio, Romero, Antonio, Olave, M. Teresa, García Belmonte, Daniel, and Queipo de Llano, M. Paz

Subjects
ANTIFUNGAL agents, MYCOSES, ASPERGILLUS, ECHINOCANDINS, CANDIDA, DRUG efficacy, MEDICATION safety, DRUG toxicity
Abstract

Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2020
Full Text
View/download PDF

17. Fluorescence In Situ Hybridization (FISH) Analysis In 160 Patients with IgM Monoclonal Gammopathies

Author

Gutierrez, Norma C., primary, Magalhaes, Roberto JP, additional, García-Sanz, Ramón, additional, Vidriales, María-Belén, additional, Ocio, Enrique M., additional, Paiva, Bruno, additional, Carpio, Daniel del, additional, Caballero, Alvaro, additional, Alonso, Jennifer, additional, Lopez-Anglada, Lucia, additional, Villaescusa, Teresa, additional, Rivas, Jesus M. Hernandez, additional, Aguilar, A., additional, Martín, Alejandro, additional, Lopez, R., additional, Orfao, Alberto, additional, and Miguel, Jesus F San, additional

Published
2010
Full Text
View/download PDF

18. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.

Author

Ferrà, Christelle, Sanz, Jaime, Díaz-Pérez, Miguel-Angel, Morgades, Mireia, Gayoso, Jorge, Cabrera, José-Rafael, Villaescusa, Teresa, Sampol, María-Antonia, Fernández-Avilés, Francesc, Solano, Carlos, Ortín, Miguel, Duarte, Rafael, Cuesta, Marian, Heras, Inmaculada, de la Serna, Javier, Moraleda, José-María, Barrenetxea, Cristina, González-Vicent, Marta, Sanz, Guillermo, and Ribera, Josep-Maria

Subjects
GRAFT rejection, GRAFT versus host disease, STEM cell transplantation, NEUTROPHILS, BONE marrow, PROGENITOR cells, CONFIDENCE intervals, HEMATOPOIETIC stem cells
Abstract

Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 109/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 109/L. Eighty-nine patients with GF were reported, and 80 patients received a second SCT. The 5-year survival probability was 31% (95% confidence interval [CI]: 18-44%), and the incidences of non-relapse mortality and relapse estimated by competing risks were 47% (95% CI: 36-58%) and 21% (95% CI: 4-28%). The strategy adopted to treat GF was heterogeneous, and no approach could be unequivocally recommended for this situation. The prognosis of patients with GF was poor even after successful recovery from GF. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

19. Serum Galactomannan Versus a Combination of Galactomannan and Polymerase Chain Reaction–Based Aspergillus DNA Detection for Early Therapy of Invasive Aspergillosis in High-Risk Hematological Patients: A Randomized Controlled Trial.

Author

María Aguado, José, Vázquez, Lourdes, Fernández-Ruiz, Mario, Villaescusa, Teresa, Ruiz-Camps, Isabel, Barba, Pere, Silva, Jose T., Batlle, Montserrat, Solano, Carlos, Gallardo, David, Heras, Inmaculada, Polo, Marta, Varela, Rosario, Vallejo, Carlos, Olave, Teresa, López-Jiménez, Javier, Rovira, Montserrat, Parody, Rocío, and Cuenca-Estrella, Manuel

Abstract

Background. The benefit of the combination of serum galactomannan (GM) assay and polymerase chain reaction (PCR)–based detection of serum Aspergillus DNA for the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological patients remains unclear. Methods. We performed an open-label, controlled, parallel-group randomized trial in 13 Spanish centers. Adult patients with acute myeloid leukemia and myelodysplastic syndrome on induction therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 ratio) to 1 of 2 arms: “GM-PCR group” (the results of serial serum GM and PCR assays were provided to treating physicians) and “GM group” (only the results of serum GM were informed). Positivity in either assay prompted thoracic computed tomography scan and initiation of antifungal therapy. No antimold prophylaxis was permitted. Results. Overall, 219 patients underwent randomization (105 in the GM-PCR group and 114 in the GM group). The cumulative incidence of “proven” or “probable” IA (primary study outcome) was lower in the GM-PCR group (4.2% vs 13.1%; odds ratio, 0.29 [95% confidence interval, .09–.91]). The median interval from the start of monitoring to the diagnosis of IA was lower in the GM-PCR group (13 vs 20 days; P = .022), as well as the use of empirical antifungal therapy (16.7% vs 29.0%; P = .038). Patients in the GM-PCR group had higher proven or probable IA–free survival (P = .027). Conclusions. A combined monitoring strategy based on serum GM and Aspergillus DNA was associated with an earlier diagnosis and a lower incidence of IA in high-risk hematological patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

20. Uveitis and Myositis as Immune Complications in Chemorefractory NK/T-Cell Nasal-Type Lymphoma Successfully Treated with Allogeneic Stem-Cell Transplant

Author

José Gómez-Crespo, Maria, García-Raso, Aránzazu, Luis López-Lorenzo, Jose, Villaescusa, Teresa, Rodríguez-Pinilla, María, Fortes, José, Serrano, Cristina, Machan, Salma, Llamas, Pilar, and Córdoba, Raúl

Abstract

NK/T-cell lymphomas are a group of clonal proliferations of NK- or, rarely, T-cell types and have peculiar clinicopathologic features. Most common site of involvement is the upper aerodigestive tract (nasal cavity, nasopharynx, paranasal sinuses, and palate). Association of autoimmune paraneoplastic disorders with NK/T-cell lymphomas is not well studied. Our patient was diagnosed with NK/T-cell lymphoma stage IV with skin involvement and treated frontline with CHOEP regimen. While he was under treatment, two immune complications presented: anterior uveitis of autoimmune origin refractory to steroids and myositis in lower limbs muscles. Autologous transplantation was rejected due to confirmed early relapse after first-line treatment, and the patient received second-line treatment according to the SMILE scheme, reaching complete response after four cycles. The patient underwent allogeneic transplantation and at the time of manuscript preparation is alive despite multiple complications. The disease should be suspected in patients with rhinitis or recurrent sinusitis, and early biopsy is recommended for all patients to avoid a delay in diagnosis. Our patient also presented symptoms of disease progression after first-line treatment, representing a paraneoplastic process, a very rare phenomenon in T-type lymphomas. This case is novel for the appearance of an inflammatory myositis, a histologically verified paraneoplastic phenomenon that responded to treatment for lymphoma.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results